Omega-3 Polyunsaturated Fatty Acids and Heart Rate Variability by Jeppe Hagstrup Christensen
REVIEW ARTICLE
published: 16 November 2011
doi: 10.3389/fphys.2011.00084
Omega-3 polyunsaturated fatty acids and heart rate
variability
Jeppe Hagstrup Christensen*
Department of Nephrology, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark
Edited by:
George E. Billman, The Ohio State
University, USA
Reviewed by:
George E. Billman, The Ohio State
University, USA
Ruben Coronel, Academic Medical
Center, Netherlands
Hester M. Den Ruijter, University of
Amsterdam, Netherlands
*Correspondence:
Jeppe Hagstrup Christensen,
Department of Nephrology, Aalborg
Hospital, Aarhus University Hospital,
Mølleparkvej 4, 9100 Aalborg,
Denmark.
e-mail: jeppe.hagstrup.christensen@
rn.dk
Omega-3 polyunsaturated fatty acids (PUFA) may modulate autonomic control of the heart
because omega-3 PUFA is abundant in the brain and other nervous tissue as well as in
cardiac tissue. This might partly explain why omega-3 PUFA offer some protection against
sudden cardiac death (SCD). The autonomic nervous system is involved in the pathogen-
esis of SCD. Heart rate variability (HRV) can be used as a non-invasive marker of cardiac
autonomic control and a low HRV is a predictor for SCD and arrhythmic events. Studies
on HRV and omega-3 PUFA have been performed in several populations such as patients
with ischemic heart disease, patients with diabetes mellitus, patients with chronic renal
failure, and in healthy subjects as well as in children. The studies have demonstrated a
positive association between cellular content of omega-3 PUFA and HRV and supplemen-
tation with omega-3 PUFA seems to increase HRV which could be a possible explanation
for decreased risk of arrhythmic events and SCD sometimes observed after omega-3 PUFA
supplementation. However, the results are not consistent and further research is needed.
Keywords: omega-3 polyunsaturated fatty acids, sudden cardiac death, autonomic function, heart rate variability
INTRODUCTION
Cardiac autonomic control is important in the pathogenesis of
sudden cardiac death (SCD). Increased vagal activity is consid-
ered protective against SCD (Billman et al., 1982; Schwartz et al.,
1984, 1992; Schwartz, 1998; Airaksinen, 1999) whereas sympa-
thetic activity favors the development of cardiac arrhythmias (Task
Force of the European Society of Cardiology, and the NorthAmer-
ican Society of Pacing and Electrophysiology, 1996). The modu-
lation of autonomic control and a change in vagal tone and/or
sympathetic tone may therefore be of major importance for the
prevention of SCD (La Rovere et al., 1998).
Possible mechanisms for the protection against SCD from
marine omega-3 polyunsaturated fatty acids (PUFA) are a topic
in this issue of the Journal. Omega-3 PUFAs are components
of membrane phospholipids throughout the body but particular
docosahexaenoic acid (DHA) is highly concentrated in the cen-
tral nervous system where it facilitates neuronal growth and has
neuroprotective effects (Beltz et al., 2007; Innis, 2008; Niemoller
and Bazan, 2010). As DHA is also abundant in cardiac tissue it is
likely that omega-3 PUFA might modulate autonomic control of
the heart. This paper reviews the studies on omega-3 PUFA and
heart rate variability (HRV) in humans. HRV is a non-invasive
marker of cardiac autonomic tone.
HEART RATE VARIABILITY AND HOW CAN IT BE USED?
During sinus rhythm heart rate (HR) and its inverse, the RR-
interval, vary from beat-to-beat mainly in response to changes
Abbreviations: CRF, chronic renal failure; DHA, docosahexaenoic acid; DM, dia-
betes mellitus; EPA, eicosapentaenoic acid; IHD, ischemic heart disease; LF/HF,
low frequency band/high-frequency band; MI, myocardial infarction; PUFA,
polyunsaturated fatty acids; SCD, sudden cardiac death.
in autonomic function. This beat-to-beat variation termed HRV
is a non-invasive method to assess cardiac autonomic tone (Task
Force of the European Society of Cardiology, and the NorthAmer-
ican Society of Pacing and Electrophysiology, 1996). HRV indices
(and especially 24-h measurements) seems to be stable and free of
placebo effects andHRV indicesmay thus be a useful tool in assess-
ing the effect of intervention therapies on autonomic function
of the heart (Task Force of the European Society of Cardiology,
and the North American Society of Pacing and Electrophysiology,
1996).
Heart rate variability can be obtained during a short time
period or from 24-h Holter recordings. It can be analyzed in the
time domain and frequency domain, or by non-linear methods.
Time domain indices (most often used) are based on normal-to-
normal beat intervals (RR) but time and frequency domain HRV
are closely associated (Kleiger et al., 1991, 2005; Bigger Jr. et al.,
1992a).
Two forms of time domain HRV indices are used: (a) data
derived directly from the RR interbeat intervals and (b) data
derived from differences between successive RR-intervals. Inter-
beat interval measures are inﬂuenced by both short term (e.g.,
respiratory) and long-term (e.g., circadian) changes (Kleiger et al.,
1992).Other timedomain indices basedon comparisons of lengths
of adjacent cycles primarily reﬂects vagal modulation of the sinoa-
trial node (Kleiger et al., 1992). Abbreviations of some important
time domain HRV indices are listed in Table 1.
Studies using frequency domain analyses (Task Force of the
European Society of Cardiology, and the North American Soci-
ety of Pacing and Electrophysiology, 1996; Akselrod et al., 1981;
Pomeranz et al., 1985) assessed with spectral analysis have iden-
tiﬁed a low frequency (LF) band (0.04–0.15Hz) reﬂecting both
sympathetic and parasympathetic inﬂuences (Kingwell et al., 1994;
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Table 1 | Definition of time domain HRV variables obtained from 24-h
Holter recordings.
Variable Units Description
RR ms Mean of all normal RR-intervals in the 24-h recording
SDNN ms SD of all normal RR-intervals in the 24-h recording
SDNN index ms Mean of the SD of all normal RR-intervals for all
5-min segments in the 24-h recording
SDANN index ms SD of the mean of all normal RR-intervals measured
in successive 5-min periods
RMSSD ms The square root of the mean of the sum of squares
of differences between adjacent RR-intervals in the
24-h recording
pNN50 % Percentage of successive RR-interval differences
>50ms during the 24-h recording
Modiﬁed from Christensen (2003).
Srinivasan et al., 2002; Murray, 2003), and a high-frequency
(HF) band (0.15–0.5Hz), corresponding to respiratory frequency,
attributed to parasympathetic inﬂuences (Akselrod et al., 1981;
Pomeranz et al., 1985; Pagani et al., 1986). The LF/HF ratio has
been considered to reﬂect cardiovascular sympathovagal balance
(Pagani et al., 1988; Furlan et al., 1990), but the degree towhich this
ratio provides a comparison between sympathetic and parasympa-
thetic inﬂuences has been questioned (Eckberg, 1997; Karemaker,
1999; Pivik and Dykman, 2004).
An attenuatedHRVcan reﬂect an increased sympathetic and/or
decreased vagal modulation. These autonomic changes have been
associatedwith an increased risk of malignant ventricular arrhyth-
mias and SCD (Barron andLesh, 1996; Schwartz, 1998;Airaksinen,
1999). Thus, a question of major importance is whether it is possi-
ble to increase HRV and if such an increase would improve clinical
outcome. This is not fully answered yet but several pharmacolog-
ical interventions resulting in an improved patient survival are
associated with an increased HRV (Christensen, 2003).
The data from epidemiological and interventional studies on
the possible beneﬁcial effect of omega-3 PUFA on SCD makes it
of importance whether such an effect can be partly explained by
modulation of cardiac autonomic control as evaluated by HRV.
Interventional studies on omega-3 PUFA and HRV in humans are
summarized in Table 2, and the individual studies are dealt with
in more detail below.
OMEGA-3 PUFA AND HRV EARLY IN LIFE
The incorporation of omega-3 PUFA in synaptic membranes
could potentially inﬂuence the autonomic control of the heart.
The progressivematuration of the autonomic nervous systemdur-
ing fetal and early life (Massin and von Bernuth, 1997) renders
this period a sensitive time, during which supplementation with
omega-3 PUFA might exert long-term effects on vagal tone and
hence HRV. Studies on HRV and omega-3 supplementation in
infants have been performed. In a study by Larnkjaer et al. (2006),
no overall effect of omega-3 PUFA supplementation to lactating
mothers was found on HRV in the 2.5-year-old offspring. How-
ever, in a gender speciﬁc analysis, a HRV increasing effect was
found in girls.
In another Danish study, 83 healthy infants were random-
ized to omega-3 PUFA supplementation or no supplementation
at 9–12months of age (Lauritzen et al., 2008). In 57 infants,
0.5-h ECG recordings were successfully obtained before and
after the intervention (3months). Omega-3 PUFA supplemen-
tation raised erythrocyte omega-3 PUFA content (p< 0.001). An
omega-3 PUFA× gender interaction was observed on mean RR-
interval (p = 0.001)with a 6% longermeanRR-interval in ﬁsh-oil-
supplemented boys (p = 0.007). Irrespective of gender, there was a
positive association between the 9- and 12-month changes in RR-
interval and erythrocyte omega-3 PUFA (p< 0.001). In infants
with conﬁrmed changes in erythrocyte omega-3 PUFA, mean RR-
interval was found to be longer (p = 0.011) in the omega-3 PUFA
supplemented group. This study concluded that omega-3 PUFA
might affect heart rhythm in infants similar to that observed in
some studies with adults.
In a study with a complex design Pivik et al. (2009) studied
the effect of early infant diet including omega-3 PUFA on HR
and HRV during the ﬁrst 6months of life. In the infants fed a
DHA-deﬁcient diet, higher HR and lower values for HRV mea-
sures were observed and the authors concluded that these ﬁndings
indicated decreased parasympathetic tone in the DHA-deﬁcient
group. These effects appeared at 4months of age and continued
for the remaining 2months of the study period, and the ﬁndings
are consistent with suggestions that the 3- to 5-month postna-
tal interval may be an important period in the development of
cardiovascular regulation. It should be emphasized that the acute
and long-term clinical consequences of a slightly lower HR or
improved HRV in infancy are, however, not known.
OMEGA-3 PUFA AND HRV IN PATIENTS WITH HEART
DISEASE
Patients with ischemic heart disease (IHD) are at higher risk of
SCD (Zipes and Wellens, 1998), and often have depressed HRV.
The association between ﬁsh consumption, the content of omega-
3 PUFA in cell membranes and HRV was evaluated in 52 patients
with a previous MI and a decreased left ventricular ejection frac-
tion (≤0.40; Christensen et al., 1997). Subjects who consumed
ﬁsh at least once a week had a slightly (non-signiﬁcant) higher
SDNN compared to those never eating ﬁsh. These data may be in
accordance with the data from Siscovick et al. (2000), and from
the US Physicians Health Study (Albert et al., 1998) showing an
approximately 50% reduction in the risk of SCD by eating ﬁsh
once a week, However, these studies included patients without
documented IHD although IHD is often the substrate for SCD
(Zipes and Wellens, 1998).
It may be the actual membrane level of omega-3 PUFA that
determines the susceptibility to develop arrhythmias and SCD
(Siscovick et al., 1995; Albert et al., 2002). In the study above
(Christensen et al., 1997), the content of omega-3 PUFA was
measured in platelets and a close positive association was found
between DHA and HRV. Such an association could indicate that
supplementation with omega-3 PUFA would increase HRV and
this hypothesis was tested in these high-risk patients (Christensen
et al., 1996). The subjects were randomized to 5.2 g of omega-3
PUFA daily (8 capsules) for 12weeks or a comparable amount of
olive oil. The HRV parameter SDNN increased signiﬁcantly from
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Table 2 | Interventional studies in humans with omega-3 PUFA and heart rate variability measurements.
Reference Population Number
(total)
Omega-3
PUFA
(daily dose)
Duration
of the
intervention
HRV indices Result
Christensen et al.
(1996)
Coronary artery disease 49 5.2 g 12weeks Time domain (24-h) +
Christensen et al.
(1998)
Dialysis patients 29 5.2 g 12weeks Time domain (24-h) (+)
Christensen et al.
(1999)
Healthy 60 2.0 or 6.6 g 12weeks Time domain (24-h) +
Villa et al. (2002) Coronary heart disease 10 3.0 or 6.0 g 4weeks Time and frequency domain (24-h) (+)
Geelen et al. (2003) Healthy 84 3.5 g 12weeks Time and frequency domain 10min −
Dyerberg et al. (2004) Healthy males 8weeks Time domain (24-h) −
Holguin et al. (2005) Nursing home residents 52 2.0 g 4months 6min repeatedTime and
frequency domain
+
Romieu et al. (2005) Nursing home residents 50 2.0 g 5months 6min repeatedTime and
frequency domain
+
O’Keefe et al. (2006) Coronary artery disease 18 1.5 g 2×4months
(cross-over)
76minTime and frequency domain +
Hamaad et al. (2006) Coronary artery disease 38 1.0 g 12weeks 76minTime and frequency domain −
Larnkjaer et al. (2006) Infants (2.5 years of age) 69 4.5 g Given to the mothers
during 4months of
lactation. The infants
were then examined
at 2.5 years of age
30minTime domain (+)
Svensson et al. (2007) Dialysis patients 30 1.7 g 12weeks 24 hTime domain −
Santini et al. (2007) Type 2 diabetes 15 1.0 g 6months 24 h Frequency domain (+)
Lauritzen et al. (2008) Infants (9–12months of age) 83 0.9 g 3months 30minTime domain (+)
Ninio et al. (2008) Overweight adults 65 6.0 g 12weeks 20min Frequency domain +
DeGiorgio et al. (2008) Patients with epilepsy 11 2.9 g 12weeks (cross-over) 60minTime domain (+)
Pivik et al. (2009) Infants (0–6months) 102 Unknown 6months 5min (repeated) Frequency
domain
(+)
Carney et al. (2010) Depressed patients with
coronary artery disease
37 2.0 g 10weeks 24 h Frequency domain +
Hansen et al. (2010) Prison inmates 13 1.7 g 23weeks 5min Frequency domain +
Kim et al. (2011) Patients with mixed
dyslipidemia
62 4.0 g 6weeks 24 hTime and frequency domain −
A + in the Result column indicates a beneﬁcial effect on HRV, a (+) indicates that subanalysis of the data revealed a beneﬁcial effect on HRV, and − indicates no
effect on HRV.
115 to 124ms in the omega-3 PUFA group. Thus, this was the
ﬁrst study indicating that omega-3 PUFA could beneﬁcially mod-
ulate cardiac autonomic control in IHDpatients.Another study,by
Russo et al. (1995) published 1 year earlier, has in previous papers
been referred to as having measured HRV in hypertensive patients
given omega-3 PUFA or placebo. They did not Holter monitor the
patients nor did they obtain an ECG in these patients. However,
they measured HR from ambulatory blood pressure recordings
which is equal to HR measured four times per hour during the
day and two times per hour during the night. They then reported
the SD from these spot measurements as HRV. Thus, this inter-
esting paper did not report HRV according to the usual deﬁnition
where the beat-to-beat variation obtained in a continuous ECG
recording is termed HRV.
Ischemic heart disease is the predominant underlying disease
behind SCD (Zipes and Wellens, 1998). HRV was measured in
291 patients referred for coronary angiography due to suspected
IHD and these measures were related to cell membrane and adi-
pose tissue levels of omega-3 PUFA (Christensen et al., 2001a).
Signiﬁcant positive correlations were found between time domain
HRV indices and levels of omega-3 PUFA, especially DHA. These
associations remained signiﬁcant also after controlling for several
possible confounders.
In a smaller cross-over trial in 10 patients with IHD, HRV,
and DHA correlated positively after dietary supplementation with
omega-3 PUFA (Villa et al., 2002). A decrease in the low frequency
band/high-frequency band (LF/HF) was found after having sup-
plemented these patients with 6 g of omega-3 PUFA for 4weeks. A
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low LF/HF is considered to reﬂect a favorable vagal predominance
thus suggesting a protection against SCD.
O’Keefe Jr. et al. (2006) randomized 18 men with a history of
MI and ejection fractions <40% to omega-3 PUFA (585mg of
DHA and 225mg of EPA) or placebo for two 4-month periods
in a cross-over design. At the end of each period, HR, HRV, and
the rate of HR recovery after exercise were determined. Omega-3
PUFA supplementation decreased HR at rest and increased HRV
only in the high-frequency (HF) band. Thus, these changes may
also be consistent with an increase in vagal activity.
A smaller single blinded study in 38 post-MI patients using 20-
min ECG recordings did not show any changes in HRV indices
in the time domain nor in the frequency domain after 3months
of supplementation with omega-3 PUFA or usual care (Hamaad
et al., 2006). Nearly 70% of these patients were on beta-adrenergic
receptor blockers and/or ACE-inhibitor therapy, agents known to
improve HRV. Furthermore, high-risk patients with ventricular
ejection fractions <40% and probably a low HRV, were excluded
from this study. It is possible that the patients from this study
would be the ones who would beneﬁt most from omega-3 PUFA
supplementation. The incorporation of omega-3 PUFA in phos-
pholipids were not measured in this study and rather surprisingly
the authors did not ﬁnd any effect of omega-3 PUFA on serum
triglycerides in these patients. A triglyceride lowering effect of
omega-3 PUFA is one of the most consistent ﬁndings (Eslick et al.,
2009) and in general such a ﬁnding indicates good compliance.
Nodari et al. (2009) investigated the effect of omega-3 PUFA
on HRV in 44 patients with idiopathic dilated cardiomyopathy.
These patients were without documented IHD. They were ran-
domized to 1 g capsules of omega-3 PUFA or olive oil capsules for
6months. Compliance was monitored by measuring the plasma
levels of omega-3 PUFA before and after intervention. Frequency
domain HRV indices were measured and the LF/HF ratio showed
a 55% decrease in the treatment group versus a 54% increase in
the placebo group. Thus, these results indicated a favorable shift
in the cardiac autonomic balance.
Low intake of omega-3 PUFA is associated with depression and
low HRV. Carney et al. (2010) therefore examined the effect of
omega-3 PUFA on HRV in depressed patients with coronary heart
disease. They randomized 72 patients to 2 g of omega-3 PUFA
daily or placebo on top of their antidepressive medication (ser-
traline) for 10weeks. They measured the frequency domain HRV
parameter very low frequency (VLF) before and after supplemen-
tation. VLF is strongly correlated to arrhythmic death after an
acute MI (Bigger Jr. et al., 1992b). VLF did not change over time
in the omega-3 PUFA group but decreased in the placebo group
which led the authors to suggest that omega-3 PUFA may have
prevented or slowed deterioration in cardiac autonomic function
in these high-risk patients.
OMEGA-3 PUFA AND HEART RATE VARIABILITY IN OTHER
POPULATIONS
DIABETES MELLITUS
The Framingham study was the ﬁrst epidemiological report
demonstrating a two to fourfold increased risk of angina pec-
toris and acute MI in diabetes mellitus (DM) patients (Kannel
and McGee, 1979). These patients also have an excess post-MI
mortality (Mak and Topol, 2000). Autonomic neuropathy involv-
ing the heart may be of importance and cardiac autonomic
neuropathy carries an excess risk of mortality in patients with
DM, including a high risk of SCD (Maser and Lenhard, 2005).
HRV analysis is a well established tool in the early detection of
autonomic neuropathy in patients with DM (Stein and Kleiger,
1999).
Heart rate variability was examined in 43 type 1 and 38 type 2
diabetes patients and related to omega-3 PUFA content in platelet
membranes (Christensen et al., 2001b). In type 1 DM patients
HRV increased with increasing levels of DHA. Furthermore, this
positive correlation between HRV and platelet DHA was more
pronounced in patients with type 1 DM solely receiving insulin
therapy and without signs of diabetic complications. However,
this study could not demonstrate a signiﬁcant association between
omega-3 PUFA and HRV in the patients with type 2 DM. In con-
trast, a small Italian study found that 6months of omega-3 PUFA
treatment in a group of 13 type 2 DM patients partially improved
HRV in the frequency domain (Santini et al., 2007).
Overweight persons with an increased risk of type 2 DM
have an impaired HRV (Ninio et al., 2008). In a randomized,
double-blind, parallel comparison, 65 overweight volunteers con-
sumed DHA 1.56 g/day and EPA 0.36 g/day or sunﬂower-seed oil
(placebo) for 12weeks (Ninio et al., 2008). In 46 of these subjects
HRV was assessed in the frequency domain using 20min ECG
recordings. Omega-3 PUFA supplementation improved HRV by
increasing HF power, representing parasympathetic activity, and
it also reduced HR at rest and during submaximal exercise. Thus,
the authors concluded that dietary supplementation with DHA-
rich ﬁsh oil reduced HR and modulated HRV in a favorable way
in these overweight subjects with a high risk of IHD.
CHRONIC RENAL FAILURE
Approximately 50% of the mortality in patients with chronic renal
failure (CRF) receiving dialysis is due to cardiovascular disease and
it is estimated that SCD accounts for approximately 30% of total
mortality in patients with end stage renal disease (ESRD; Herzog
et al., 2008). Cardiac autonomic dysfunction is very frequent in
these patients (Barron and Lesh, 1996) with a high prevalence of
ventricular arrhythmias. An attenuated HRV confers signiﬁcant
prognostic value in end stage renal failure patients (Chandra et al.,
2011) as well as in other CRF patients (Oikawa et al., 2009). HRV
may also identify patients at increased risk of SCD (Hayano et al.,
1999).
Omega-3 PUFA may be beneﬁcial for dialysis patients (Fried-
man and Moe, 2006) and could also have several beneﬁcial effects
in chronic kidney disease patients not treated with dialysis (Fassett
et al., 2010). Three studies have examined the effect of omega-
3 PUFA on HRV in ESRD patients. The ﬁrst study included 29
patients and examined the association between the content of
omega-3 PUFA in granulocyte membranes and HRV (Christensen
et al., 1998). Furthermore, the patients were randomly allocated
to dietary supplementation with either 5.2 g of omega-3 PUFA or
olive oil for 12weeks. Only 17 patients completed the study (11
from the omega-3 PUFA group and 6 controls). This hampered
comparisons between the two groups, but in the omega-3 PUFA
group no increase in HRV was observed after supplementation
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whereas the mean RR-interval increased. These patients had very
low HRV indices and also low levels of omega-3 PUFA at baseline.
This is in accordance with recent data (Madsen et al., 2011). The
narrow ranges of bothHRV indices andomega-3PUFAvaluesmay
partly explain the lack of association between HRV and omega-
3 PUFA at baseline. Thus, an increase in the range of omega-3
PUFA levels after dietary supplementation led to a signiﬁcant pos-
itive correlation between omega-3 PUFA in granulocytes and the
HRV parameter SDNN. Also, when the patients completing the
trial were dichotomized according to their median SDNN, the
omega-3 PUFA level was highest among those with the highest
SDNN.
In an uncontrolled design, Fiedler et al. (2005) gave 1.2 g of
omega-3 PUFA daily for 12weeks to 11 hemodialysis patients.
A number of cardiovascular risk factors were measured and the
authors wrote they measured HRV. However, this variability was
reported as 60–102 versus 61–105 beats/min before and after sup-
plementation (NS).Thiswasnot a continuous recordingof theRR-
interval, and, therefore, does not provide a measurement of HRV.
In a subgroup of a larger population with ESRD and docu-
mented cardiovascular disease, Svensson et al. (2007), randomized
30 patients to 1.7 g of omega-3 PUFAdaily or placebo (olive oil) for
3months. This study could not ﬁnd any effect on HRV by omega-
3 PUFA supplementation but a non-signiﬁcant trend toward a
reduced HR was observed in the omega-3 PUFA arm. It is evident
that further studies are warranted regarding the effects of omega-
3 PUFA on HRV and autonomic modulation in these high-risk
patients.
HEALTHY SUBJECTS
A low HRV seems to predict a poor outcome in healthy pop-
ulations. In the “Men Born in 1913 Study” randomly selected
men aged 50 years had HRV obtained from 10 s ECG strips at
entry. During a 10-year follow-up an increased risk of death from
IHD during a 10-year was observed in men with a decreased HRV
(Tibblin et al., 1975). Also, in the Zutphen study, the 5-year age-
adjusted relative risk of mortality for subjects with a low HRV
measured from 25 to 30 s ECG strips was 2.1 in middle-aged and
1.4 in elderly men (Dekker et al., 1997),with an inverse association
between HRV and the risk of SCD. Data from the Framingham
study based on 2-h ECG recordings conﬁrm the predictive value
of a decreased HRV in the general population (Tsuji et al., 1994,
1996). Also, Molgaard et al. (1991) found an attenuated HRV in
apparently healthy subjects subsequently suffering SCD.
The effect of dietary supplementation with omega-3 PUFA on
HRV was examined in healthy subjects (Christensen et al., 1999).
In this dose–response study, 60 healthy subjects were randomly
divided into three groups receiving either (1) 2.0 g of omega-
3 PUFA, (2) 6.6 g of omega-3 PUFA, or (3) placebo (olive oil)
daily for 12weeks. Baseline examination revealed positive corre-
lations between HRV indices and DHA in men, an observation
also found by others (Brouwer et al., 2002). Overall, intervention
with omega-3 PUFA had no effect on HRV, but if these healthy
subjects were dichotomized according to their baseline median
SDNN, dietary supplementation with omega-3 PUFA (both 2.0
and 6.6 g) increased RR-interval in those subjects belonging to the
lower median. By further stratifying these subjects according to
gender, a dose-dependent increase in several HRV indices among
men was seen whereas no effect was observed in women. The
result from the male participants may emphasize the importance
of the actual cellular membrane level of omega-3 PUFA as a major
determinant of the risk of SCD (Siscovick et al., 1995; Albert et al.,
2002).
Grimsgaard et al. (1998) also showed a reduction in HR
(inversely related to RR) after supplementation with DHA to
healthy men. Indeed, several studies have shown that omega-3
PUFA reduce HR (Mozaffarian et al., 2005), which may be of
importance because an increased HR is strongly associated with a
poor cardiovascular outcome (Palatini and Julius, 2004).
In contrast, a study including 84 middle-aged subjects who
received 3.5 g of omega-3 PUFA or placebo daily for 12weeks
found no effect of omega-3 PUFA on HRV obtained from short
ECG recordings (10min; Geelen et al., 2003). Compliance was
measured in this study. The short recording time excluded the
analysis of long-term diurnal variations in heart rhythm which
could be of importance. Thus, it is unknown whether the vagal
predominance during night time is modiﬁable by omega-3 PUFA.
A study by Dyerberg et al. (2004) looked at the effect of trans-
and omega-3 PUFA on cardiovascular risk markers, among these
HRV, in healthy males. The experimental fats were incorporated
intobakery products and supplieddaily. Theomega-3PUFAgroup
received approximately 4 g of omega-3 PUFA daily. These subjects
were healthy well-trained men with a high HRV at baseline and it
was not possible to increase their HRV further during 8weeks of
supplementation.
NURSING HOME RESIDENTS
Another study addressing the effect of omega-3 PUFA on HRV
included 52 residents from a Mexican nursing home (Holguin
et al., 2005). A few of these patients had hypertension or IHD.
Omega-3 PUFA 2 g daily or soy oil 2 g daily was supplied. HRV
was assessed with 6-min readings obtained every other day for a
2-month run-in period and a 6-month supplementation period.
Both supplements improved HRV, with the omega-3 PUFA sup-
plementation being superior to soy oil capsules. There was no
analysis of the differences in response between the groups. Nev-
ertheless, this study lends support to the hypothesis that omega-3
PUFA may improve autonomic function.
In a quite similar setting and design as described above the
same group included 50 nursing residents from a Mexican nursing
home located in an environment where the residents were exposed
to particulate matter (Romieu et al., 2005). Romieu et al. reported
that omega-3 PUFA supplementation (2 g daily for 6months) pre-
vented HRV decline related to particulate matter exposure in this
study population.
OTHER SUBJECTS
In a study from Norway 53 male (mean age 35 years) inmates
from a prison were randomly assigned to intervention and con-
trol groups (Hansen et al., 2010). The intervention group received
seafood (mainly fatty ﬁsh, >8% fat) for dinner three times per
week for a period of 6months. Both groups were requested to
eat their usual diet provided by the prison. Blood samples were
collected and 5-min ECG recordings were obtained in order to
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analyze HRV (HF and LF power) before and after the 6-months
study period. Due to various reasons only 13 subjects completed
the trial but a signiﬁcant reduction in the sympathovagal balance
(decrease in LF/HF) was observed in the intervention group.
A Korean study evaluated the effects of omega-3 PUFA and
simvastatin on lipids and lipoproteins and HRV in patients with
mixed dyslipidemia (Kim et al., 2011). Nearly 70% of the patients
had hypertension andmany received antihypertensivemedication.
Sixty-two patients were randomized into two treatment groups
given a combination treatment with 4 g of omega-3 PUFA and
20mg of simvastatin daily or a monotherapy of 20mg simvas-
tatin for 6weeks. After 6 weeks of intervention an 41% reduction
in triglycerides concentration was observed in the omega-3 PUFA
groups whereas no signiﬁcant changes was seen for HRV indices in
the time and the frequency domains (24-h recordings). This study
had a relatively short intervention period and a longer period of
supplementation could be of importance to reach steady state and
thereby a possible effect on HRV.
Sudden unexpected death in epilepsy (SUDEP) is a major cause
of death in epilepsy. It accounts for up to 20% of mortality and a
smaller pilot study examined the effect of omega-3 PUFA supple-
mentation to patients with intractable epilepsy (DeGiorgio et al.,
2008). Elevenpatientswere given 2880mgomega-3PUFAdaily for
12weeks and after a 6-week wash-out they were switched to soy-
bean oil (placebo). A non-signiﬁcant trend toward an increase in
time domain HRV measures was observed in only in a few patients
with a lowbaseline.Whether omega-3 PUFA improveHRV in peo-
ple with epilepsy needs to be further examined in larger controlled
clinical trials and it would also be of interest to know if omega-3
PUFA can reduce the high risk of SUDEP in epilepsy.
POPULATION-BASED INVESTIGATIONS, OMEGA-3 PUFA, AND HRV
A large study based on dietary omega-3 PUFA intake and HRV
in a well-deﬁned population was published a couple of years ago
(Mozaffarian et al., 2008).More than 4000 subjects, aged≥65 years
were included from the Cardiovascular Heart Study. Approxi-
mately 25% had DM and 20% had a history of IHD. The time
domain HRV indices SDNN and RMSSD were measured from
10-s ECG recordings in 4263 subjects and in a group of 1361 par-
ticipants, HRV in the time domain and in the frequency domain
was derived from 24-h Holter recordings. In a subset of the sub-
jects, plasma phospholipids levels of EPA and DHA was measured
and these levels correlated signiﬁcantly with the ﬁsh consumed
(r = 0.55, p< 0.001). According to the ﬁsh intake, the participants
were divided into ﬁve groups and in general, HRV was highest
among the participants with the highest ﬁsh intake. From the sub-
analyses of HRV it was suggested that a high ﬁsh consumption
was associated with an enhanced vagal activity and parasympa-
thetic predominance. Thus, this population-based study seemed
to conﬁrm that omega-3 PUFA supplementation can modulate
cardiac autonomic function in a favorable way.
Heart rate variability in relation to fruit, vegetable, and ﬁsh
consumption was reported from the Veterans Administration
Normative Aging Study (Park et al., 2009). HRV variables (4-
min recordings) were measured among 586 older men with 928
total observations from 2000 to 2007. Dietary intake was eval-
uated with a self-administered semiquantitative food–frequency
questionnaire and categorized into quartiles. No signiﬁcant asso-
ciation was seen between HRV measures and intakes of other fruit
and vegetables, vitamin C, carotenoids, tuna and dark-meat ﬁsh,
omega-3 PUFA. Thus, these data differed from the Cardiovascular
Heart Study despite a similar intake of omega-3 PUFA in both
study populations.
Inuit from Nunavik (northern Quebec) consume large
amounts of ﬁsh and marine mammals. In a cross-sectional study
the impact of omega-3 PUFA on resting HR and HRV among
Nunavik Inuit adults was assessed also considering mercury expo-
sure and other potential confounders (Valera et al., 2011). HRV
data from 2-h Holter recordings was obtained in 181 adults
≥40 years old (109 women and 72 men) living in the 14 coastal
villages of Nunavik.Omega-3PUFA levelsweremeasured inmem-
brane erythrocytes. In women, omega-3 PUFA was signiﬁcantly
associated with HRV indices also after controlling for several
potential confounders whereas such associations could not be
found in men.
SUMMARY REMARKS
Several studies have found a positive association between omega-3
PUFA and HRV (Christensen et al., 1997, 2001a,b; Brouwer et al.,
2002;Mozaffarian et al., 2008;Valera et al., 2011) although data are
not consistent (Park et al., 2009). Therefore, interventional studies
are of importance and as shown in Table 2, 8 of these 20 studies
have revealed results supporting a beneﬁcial effect on HRV and in
7 other of these trials a subanalysis of the data pointed at an effect
of omega-3 PUFA on HRV. However, 5 of the 20 trials could not
conﬁrm an effect on HRV.
The inconsistency of the trial ﬁndings could of course be due
to a truly absent treatment effect. However, most studies showed
some effect and, thus, other considerations should also be taken
into account. It is evident that the populations examined are
very heterogeneous ranging from infants to nursing home resi-
dents. However, despite this heterogeneity, these data still indicate
beneﬁcial effects in several trials.
The intervention studies are all with limited sample sizes mak-
ing conclusions susceptible to statistical errors. Furthermore, the
dose of omega-3 PUFA varied considerably as did the length of
intervention. Both issues may be of importance because some data
suggest a dose-dependent effect of omega-3 PUFA on HRV as well
as a certain time may be needed to obtain a steady state of omega-3
PUFA concentration in the relevant tissue.
Of importance are also the different methods of assessing HRV.
As seen in Table 2 HRV data are derived from recordings ranging
from 5min to 24 h. It is obvious that only 24 h recordings mea-
sure possible interactions on long-term diurnal variation in HRV.
Whether time domain or frequency domain HRV variables are
preferable is also an open question but both methods are used and
sometimes in combination. Although some evidence (see above)
support that the beat-to-beat variation in HR (HRV) reﬂects cor-
responding changes in cardiac parasympathetic regulation others
have questioned the fact that HRV should reﬂect parasympathetic
regulation (Taylor et al., 2001; Parati et al., 2006; Denver et al.,
2007). Therefore, it is of importance to emphasize that HRV does
not provide a quantitative measure of cardiac parasympathetic
nerve activity (an accurate assessment of nerve activity can only be
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obtained fromdirect nerve recordings) butmayprovide a very lim-
ited qualitative index of changes in cardiac autonomic regulation.
Thus, HRV data should always be interpreted with care.
Medications that have an impact on HRV could obscure any
effect of omega-3 PUFA on HRV in patients with coronary heart
disease or in ESRD patients. Compliance regarding the intake of
omega-3 PUFA is also of importance and it is advised that compli-
ance is assured by measuring the incorporation of these fatty acids
into phospholipids either in serum or in cell membranes. Another
issue is whether it is EPA or DHA or both that might beneﬁ-
cially affect HRV. Most data support DHA as the most important
omega-3 PUFA when it comes to modify cardiac autonomic tone.
This may be in accordance with the high concentration of DHA
in nervous tissue.
Another question of importance is whether it is the HR reduc-
ing effect of omega-3 PUFA which is of most importance (Mozaf-
farian et al., 2005)? Such an effect could also be translated into an
increased HRV. Recent data (animal study) from Billman and Har-
ris (2011) has suggested that the HRV responses to omega-3 PUFA
treatment are more consistent with reductions in the intrinsic
pacemaker rate than with alterations in autonomic neural reg-
ulation. A previous animal study in rabbits (Verkerk et al., 2009)
also found that omega-3 PUFA supplementation reduced pace-
maker current and HR. One human study supports a direct effect
of omega-3 PUFA on the heart (Harris et al., 2006). Harris et al.
found that omega-3 PUFA supplementation reduced HR in car-
diac transplant recipients. These hearts were of course denervated
and the reduction inHRcould therebynot bemediatedby a change
in vagal tone.
Finally, it can be questioned whether the relatively modest
changes in HRV induced by omega-3 PUFA really can explain
the improved cardiovascular outcome such as a reduction in SCD.
However, in this respect the possible effect on HRV is only one
of several beneﬁcial effects of omega-3 PUFA and it may be a
combination of these effects which in the end materializes in the
improved clinical outcome. In humans you can not isolate the
other effects but you can chose to monitor only one of the effects.
CONCLUSION
Both nervous tissue and heart tissue have a high content of omega-
3 PUFA (especially DHA) and this may be consistent with the
ﬁnding that this marine omega-3 fatty acid may modulate cardiac
autonomic function as assessed byHRV.Thus,omega-3PUFAmay
modulate HRV both at the level of the autonomic nervous system
and the heart. Most of the data in this review support that omega-
3 PUFA beneﬁcially modulates cardiac autonomic control thereby
possibly reducing the risk of arrhythmias. However, data are not
consistent perhaps due to a large heterogeneity in the interven-
tional trials such as small sample sizes, different populations, short
duration of intake, limited periods of HRV assessment, or variable
doses of omega-3 PUFA. Thus, further research is needed to con-
ﬁrm the possible beneﬁcially effect of omega-3 PUFA on HRV.
More work is also needed to understand the pathways through
which omega-3 PUFA may improve HRV or reduce HR.
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